Stifel Nicolaus started coverage on shares of Mentari Therapeutics (NASDAQ:MTRI – Get Free Report) in a report issued on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $30.00 price target on the stock.
Mentari Therapeutics Price Performance
Mentari Therapeutics Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases.
See Also
- Five stocks we like better than Mentari Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Mentari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mentari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
